Processa Pharmaceuticals, Inc. (PCSA): Price and Financial Metrics


Processa Pharmaceuticals, Inc. (PCSA): $0.86

-0.02 (-1.72%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add PCSA to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

PCSA Stock Price Chart Interactive Chart >

Price chart for PCSA

PCSA Price/Volume Stats

Current price $0.86 52-week high $4.52
Prev. close $0.87 52-week low $0.80
Day low $0.80 Volume 82,841
Day high $0.95 Avg. volume 45,367
50-day MA $1.47 Dividend yield N/A
200-day MA $2.37 Market Cap 13.67M

Processa Pharmaceuticals, Inc. (PCSA) Company Bio


Processa Pharmaceuticals, Inc. operates as a pharmaceutical company. The Company focuses on development of drug products that are intended to improve the survival and quality of life for patients who have unmet medical need. Processa Pharmaceuticals serves patients in the United States.


PCSA Latest News Stream


Event/Time News Detail
Loading, please wait...

PCSA Latest Social Stream


Loading social stream, please wait...

View Full PCSA Social Stream

Latest PCSA News From Around the Web

Below are the latest news stories about PROCESSA PHARMACEUTICALS INC that investors may wish to consider to help them evaluate PCSA as an investment opportunity.

Processa Pharmaceuticals To Present an Update on Its Future Therapeutic Focus and Strategy at the Biotech Showcase on January 11, 2023.

HANOVER, MD, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), Dr. David Young, Processa Pharmaceuticals, CEO will present an update on Processa’s future therapeutic focus and strategy at the upcoming Biotech Showcase on January 11, 2023, at 10 am. This presentation will also be accessible at https://event.webcasts.com/starthere.jsp?ei=1591773&tp_key=fbb2da9fa8 Processa management is available for one-on-one meetings with potential investors and partners in San Fra

Yahoo | January 4, 2023

Processa Pharmaceuticals Announces PCS12852 Successfully Improves the Clinical Symptoms Associated with Gastroparesis in Phase 2A Trial

A 0.5 mg daily dose of PCS12852 administered over 28 days in gastroparesis patients successfully improved gastroparesis symptoms in a clinically meaningful way as defined by greater than a 0.5 reduction in the ANMS GCSI-DD score compared to baseline.The percentage of patients who met the clinically meaningful change in symptom score was greater in the PCS12852 0.5 mg daily dose group than in the placebo or the PCS12852 0.1 mg daily dose groups.Over 28 days the mean gastroparesis symptoms score c

Yahoo | December 14, 2022

Analysts’ Top Healthcare Picks: Jazz Pharmaceuticals (JAZZ), scPharmaceuticals (SCPH)

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Jazz Pharmaceuticals (JAZZ – Research Report), scPharmaceuticals (SCPH – Research Report) and Processa Pharmaceuticals (PCSA – Research Report) with bullish sentiments. Jazz Pharmaceuticals (JAZZ) Jefferies analyst Akash Tewari maintained a Buy rating on Jazz Pharmaceuticals yesterday and set a price target of $185.00. The company's shares closed last Wednesday at $140.00. According to TipRanks.

Howard Kim on TipRanks | November 10, 2022

Processa Pharmaceuticals Announces Third Quarter Financial Results and Provides Corporate Update

PCS12852 successfully demonstrates a positive effect on the gastric emptying rate, clearing the path for a Phase 2B trial in 2023.Next Generation Capecitabine (a combination of PCS6422 and capecitabine) successfully identifies dosing regimens for a Phase 2B trial to be initiated in 2023 after a meeting with FDA to discuss the alignment of the trial design with the FDA’s Project Optimus Oncology Initiative. HANOVER, Md., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PC

Yahoo | November 8, 2022

PCS12852 Improves Gastric Emptying in Gastroparesis Patients

In a Phase 2A Proof-of-Concept trial, the Gastric Emptying Breath Test (GEBT) results demonstrated statistical improvement in gastric emptying in gastroparesis patients receiving 0.5 mg of PCS12852 (6 patients) as compared to placebo (8 patients) at a p < 0.10 level.Adverse events associated with this Phase 2A trial were mild to moderate with no clinically significant cardiovascular or serious adverse events.Evaluation of the effect of PCS12852 on gastroparesis symptoms is expected before the en

Yahoo | November 8, 2022

Read More 'PCSA' Stories Here

PCSA Price Returns

1-mo -21.82%
3-mo -59.78%
6-mo -72.78%
1-year -76.76%
3-year N/A
5-year -96.97%
YTD -21.82%
2022 -77.55%
2021 -25.70%
2020 N/A
2019 0.00%
2018 -18.18%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7024 seconds.